Abstract On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide
tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate …

Antibody drug conjugates are an exciting therapeutic modality that combines the targeting
specificity of antibodies with potent cytotoxins to selectively kill cancer cells. The targeting …

Purpose Evans blue as an albumin binder has been widely used to improve
pharmacokinetics and enhance tumor uptake of radioligands, including prostate-specific …

Simple Summary In previous studies, we described a modular Chimeric Antigen Receptor
(CAR) T cell platform which we termed UniCAR. In contrast to conventional CARs, the …

Purpose: Initially, prostate cancer responds to hormone therapy, but eventually resistance
develops. Beta emitter-based prostate-specific membrane antigen (PSMA)-targeted …

Mesothelin (MSLN) is a molecular biomarker of many types of solid tumors, such as
mesothelioma, pancreatic cancer, and colon cancer. Owing to the significant difference in …

Drugs have structural homology across similar biological targets. Small molecule drugs
have the efficacy to target specific molecular targets within the cancer cells with enhanced …

The global incidence of prostate cancer (PCa) is rising. Localized PCa can be managed
through surgical intervention or radiotherapy, but certain patients may experience …

Purpose CD30 serves as an ideal therapeutic target for lymphoma, but its variable
expression and high relapse rate pose challenges in targeted therapy. This study aims to …

Simple Summary The prostate-specific membrane antigen (PSMA) protein present in most
prostate cancer cells has emerged as a promising target for the imaging and treatment of …